Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

VRCI

Verici Dx Plc (LON:VRCI) has confirmed the result of its WRAP Retail Offer at the issue price of 0.35 pence per share, following the announcements made on 8 June 2026. The Company has raised aggregate gross proceeds of approximately £0.19 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing. Accordingly, the Company will issue a total of 53,345,832 WRAP Retail Offer Shares.

In total, the Placing and the WRAP Retail Offer has raised gross proceeds of approximately £2.6 million for the Company, via the Placing of 700,000,000 Placing Shares and the 53,345,832 WRAP Retail Offer Shares.

For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the WRAP Retail Offer Shares is conditional upon:

  • the passing of certain resolutions to be put to shareholders of Verici Dx plc at a General Meeting, which is expected to be held at Shoosmiths LLP’s London office at 1 Bow Churchyard, London EC4M 9DQ at 11.30 a.m. on 22 June 2026; and
  • the new Ordinary Shares being admitted to trading on AIM.

Terms used but not defined in this announcement have the same meaning as set out in the Company’s announcement released at 7am on 8 June 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients.

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory.

Verici Dx targets growing demand for kidney transplant diagnostics

Verici Dx is targeting the expanding kidney transplant diagnostics market as molecular surveillance becomes a larger part of post-transplant care.

Verici Dx strengthens commercial case for kidney transplant risk test

Verici Dx has published analysis showing its PTRA kidney transplant risk test could generate more than $191 million in US healthcare savings over two years.

Verici Dx secures Olink Certified Service Provider status

Verici Dx has achieved Olink Certified Service Provider status, expanding its proteomics assay capabilities at its CAP-certified and CLIA-accredited laboratory.

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption.

Search